×

Novavax down 84% after disappointing vaccine trial

4:55 PM ET Thu, 15 Sept 2016

Shares of Novavax plummeted after a drug trial failed to meet the company's goals. CNBC's Meg Tirrell reports. CNBC senior markets commentator Michael Santoli and Dani Hughes, Divine Capital, weigh in.